# Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates

> **NCT01484080** · PHASE1,PHASE2 · COMPLETED · sponsor: **Centro Nacional de Investigaciones Oncologicas CARLOS III** · enrollment: 140 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** BIBF + Paclitaxel
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01484080
- **Lead sponsor:** Centro Nacional de Investigaciones Oncologicas CARLOS III
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-11
- **Final completion:** 2014-04
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2020-01-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01484080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01484080, "Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01484080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*